Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Hematol Oncol
Main Authors: Jasra, Sakshi, Kazemi, Mohammed, Shah, Nishi, Chen, Jiahao, Fehn, Karen, Wang, Yanhua, Mantzaris, Ioannis, Kornblum, Noah, Sica, Alejandro, Bachier, LizaMarie, Goldfinger, Mendel, Gritsman, Kira, Braunschweig, Ira, Steidl, Ulrich, Shastri, Aditi, Verma, Amit
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://ncbi.nlm.nih.gov/pubmed/33397455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00186-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados